Gilead Sciences Inc. (GILD): Price and Financial Metrics

Gilead Sciences Inc. (GILD): $73.30

0.80 (-1.08%)

POWR Rating

Component Grades








Add GILD to Watchlist
Sign Up

Industry: Biotech




#1 of 356

in industry

GILD Price/Volume Stats

Current price $73.30 52-week high $89.74
Prev. close $74.10 52-week low $63.60
Day low $72.87 Volume 1,950,037
Day high $73.87 Avg. volume 5,702,251
50-day MA $76.67 Dividend yield 3.98%
200-day MA $80.07 Market Cap 91.33B

GILD Stock Price Chart Interactive Chart >


  • GILD scores best on the Value dimension, with a Value rank ahead of 97.15% of US stocks.
  • GILD's strongest trending metric is Stability; it's been moving up over the last 177 days.
  • GILD's current lowest rank is in the Momentum metric (where it is better than 3.78% of US stocks).

GILD Stock Summary

  • With a market capitalization of $93,463,536,619, GILEAD SCIENCES INC has a greater market value than 97.66% of US stocks.
  • GILD's went public 31.7 years ago, making it older than 83.38% of listed US stocks we're tracking.
  • In terms of volatility of its share price, GILD is more volatile than merely 3.85% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to GILEAD SCIENCES INC, a group of peers worth examining would be ADI, NTES, BMY, ATVI, and RTX.
  • GILD's SEC filings can be seen here. And to visit GILEAD SCIENCES INC's official web site, go to

GILD Valuation Summary

  • In comparison to the median Healthcare stock, GILD's price/sales ratio is 15% lower, now standing at 3.4.
  • Over the past 243 months, GILD's price/sales ratio has gone down 13.1.

Below are key valuation metrics over time for GILD.

Stock Date P/S P/B P/E EV/EBIT
GILD 2023-09-22 3.4 4.4 17.0 13.6
GILD 2023-09-21 3.4 4.4 17.1 13.6
GILD 2023-09-20 3.5 4.5 17.2 13.7
GILD 2023-09-19 3.4 4.5 17.2 13.7
GILD 2023-09-18 3.4 4.5 17.2 13.7
GILD 2023-09-15 3.4 4.5 17.2 13.7

GILD Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -60.73%.
  • Its 5 year net cashflow from operations growth rate is now at -41.74%.
  • The 5 year net income to common stockholders growth rate now stands at -60.73%.
Over the past 34 months, GILD's revenue has gone up $4,565,000,000.

The table below shows GILD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 27,281 9,072 4,592
2022-09-30 27,136 9,710 3,334
2022-06-30 27,515 10,100 4,137
2022-03-31 27,472 10,614 4,515
2021-12-31 27,305 11,384 6,225
2021-09-30 27,482 10,095 7,394

GILD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GILD has a Quality Grade of B, ranking ahead of 89.87% of graded US stocks.
  • GILD's asset turnover comes in at 0.406 -- ranking 114th of 682 Pharmaceutical Products stocks.
  • ENTA, RDUS, and ADMS are the stocks whose asset turnover ratios are most correlated with GILD.

The table below shows GILD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.406 0.805 0.259
2021-06-30 0.402 0.801 0.179
2021-03-31 0.405 0.806 0.066
2020-12-31 0.403 0.815 0.058
2020-09-30 0.389 0.790 0.058
2020-06-30 0.375 0.786 0.009

GILD Price Target

For more insight on analysts targets of GILD, see our GILD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $75.84 Average Broker Recommendation 1.7 (Moderate Buy)

Gilead Sciences Inc. (GILD) Company Bio

Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases. Daniel O’Day has been Gilead Science’s Chief Executive Officer since March of 2019 and the company is headquartered in Foster City, California. With over 10,000 employees worldwide, the company has operations in North America, Asia, the Middle East and Europe. As of 2019, the company had global sales of $22.1 billion. Some of Gilead Science’s major competitors are Novo Nordisk A/S ADR (NVO), Biogen Inc. (BIIB), and Novartis AG ADR (NVS).

GILD Latest News Stream

Event/Time News Detail
Loading, please wait...

GILD Latest Social Stream

Loading social stream, please wait...

View Full GILD Social Stream

Latest GILD News From Around the Web

Below are the latest news stories about GILEAD SCIENCES INC that investors may wish to consider to help them evaluate GILD as an investment opportunity.

3 Magnificent Dividend Stocks to Buy in October

There's no better time than October to invest in high-quality dividend stocks. Three Motley Fool contributors believe they've identified magnificent dividend stocks to buy in October. Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ).

Yahoo | September 30, 2023

Here's Why We Think Gilead Sciences (NASDAQ:GILD) Might Deserve Your Attention Today

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Yahoo | September 27, 2023

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $75.53, moving +0.94% from the previous trading session.

Yahoo | September 26, 2023

Unveiling Gilead Sciences (GILD)'s Value: Is It Really Priced Right? A Comprehensive Guide

An in-depth analysis of Gilead Sciences' intrinsic value, financial strength, profitability, and growth

Yahoo | September 26, 2023

Why Gilead Sciences, Inc. (NASDAQ:GILD) Looks Like A Quality Company

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Yahoo | September 23, 2023

Read More 'GILD' Stories Here

GILD Price Returns

1-mo -3.43%
3-mo -4.17%
6-mo -10.36%
1-year 22.06%
3-year 33.81%
5-year 17.08%
YTD -12.12%
2022 23.63%
2021 29.95%
2020 -6.70%
2019 7.88%
2018 -9.92%

GILD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GILD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!